About this trial
Denosumab is used for the prevention of skeletal related events in adults with bone metastases from solid tumours. Significant symptomatic and survival benefits have also been demonstrated with the use of the anti-androgens e.g. Enzalutamide in patients with advanced castration resistant prostate cancer. This study investigates the progression free survival of patients treated with a combination of Denosumab and Enzalutamide in progressive metastatic castrate-resistant prostate cancer. Patients receive a subcutaneous injection of Denosumab on day 1 of each 4 week cycle for 24 cycles and Enzalutamide capsules 160mg orally daily. All patients who are eligible for this study receive both Denosumab and Enzalutamide. Patients will attend for a study visit every 4 weeks for approximately 24 months.
Localized Intermediate Risk Prostate Cancer
Where’s this trial being run?Cork University Hospital, Sligo University Hospital, Tallaght University Hospital, St Vincents University Hospital, University Hospital Limerick, University Hospital Galway, and University Hospital Waterford
Can I join this study / trial?
The first thing you do is to talk to your doctor and/or the cancer trials research team in your hospital. The contact details for the cancer trials research units in Ireland is here.
Why not Print this page and bring it with you. It will help your doctor and research team advise you.Print this page
For more detailed informationClick Here
DICE Study A Phae II study of Denosumab In Combination with Enzalutamide in progressive metastatic castrate-resistant prostate cancer and bone metastases
Cancer Trials Ireland
Global: February 2019
Ireland: February 2019
|Global Recruitment Target:||NA Ireland only|
|Ireland Recruitment Target:||88|